← All trials
NCT05569941
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2022
- Primary completion
- Mar 13, 2023
- Completion date
- Mar 20, 2023
- First posted
- Oct 6, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 62
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assembly BiosciencesLead sponsor
- New Zealand Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.